The FDA has issued new guidelines entitled "Clinical Pharmacology Data
to Support a Demonstration of Biosimilarity to a Reference Product." These guidelines provide additional detail regarding the clinical data and information needed to demonstrate that a proposed product is "highly similar" to a reference product.
This is going to require some time to digest.
No comments:
Post a Comment